Last week, Elle Investments published a Top Idea on Spectrum Pharmaceuticals (SPPI). For a look behind the idea, please see their interview with the PRO+ team.
Seeking Alpha: Can you briefly summarize your bullish thesis for readers who may not have seen it yet?
Elle Investments: During 2017 and through mid-2018, SPPI rose to over $20.00/share based on the outstanding objective response rates (ORRs) seen in a phase 2 trial for lead candidate poziotinib conducted by MD Anderson Cancer Center for patients with non-small cell lung cancer (NSCLC) with an exon 20 mutation. Initial ORR